Cancer vaccination therapy by using VEGFRs-targeted peptides in the patients who have received trans-arterial chemo-embolization (TACE) against hepatocellular carcinoma -A randomized double blind study-

UMIN ID: UMIN000001731

Registered date:23/02/2009

Basic Information

• Health condition(s) or Problem(s) studied: hepatocellular carcinoma
• Date of first enrollment: 2009/02/01
• Target sample size: 30
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Cancer vaccination therapy by using VEGFRs-targeted peptides in the patients who have received trans-arterial chemo-embolization(TACE) against HCCs
Cancer vaccination therapy by IFA in the patients who have received trans-arterial chemo-embolization(TACE) against HCCs

Outcome(s)

• Primary Outcome: safety
• Secondary Outcome: immunological respose and clinical efficacy

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: 1. Patients have more than 10 tumors in the liver before TACE treatment. 2. Patients have major portal vein thrombosis. 3. Patients have extrahepatic metastasis. 4. Patients have uncontrollable associated cancer. 5. Patients have uncontrollable severe infectional diseases. 6. Patients have trauma. 7. Patients who are treated with steroid or immunotherapy during clinical trial. 8. Pregnancy or lactation. 9. Patients who are inappropriate.

Related Information

• Primary Sponsor: Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences Kumamoto University
• Source(s) of Monetary Support: Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences Kumamoto University